Dyax Corp. Issued Seventh U.S. Patent in Its Phage Display Patent Portfolio

03-May-2007

Dyax Corp. announced that the United States Patent and Trademark office issued U.S. Patent No. 7,208,293, Dyax's seventh U.S. patent covering its proprietary protein display technology. This new patent provides Dyax with additional patent claims that cover methods for selecting binding proteins, such as antibodies, through the use of eukaryotic cell surface display. In addition to its seven U.S. patents, Dyax holds several issued patents for phage display in Canada, Israel, and Japan, with pending applications in other countries.

"This newly issued patent strengthens Dyax's already dominant patent portfolio position in the field of protein display," stated Dr. Ivana Magovcevic-Liebisch, Dyax's General Counsel and Executive Vice President of Administration. "Our broad technology platform continues to provide Dyax and our collaborators with the ability to develop novel compounds through both phage and yeast display."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous